Importantly, two compounds were confirmed to display synergism (defined by a greater than additive effect) with trametinib in reducing tumour size: volasertib (Polo-like kinase inhibitor) (Schöffski, 2009) and ritanserin [serotonin receptor 5-HT2A/2C and DGKα inhibitor (Boroda et al., 2017; Leysen et al., 1985)] (Fig. 2; Fig. S3). The gene discussed is DGKA; the disease is neoplasm.